Hormone Therapy & Tirzepatide: 35% More Weight Loss After Menopause

A recent study conducted by researchers at Mayo Clinic suggests a potential benefit for postmenopausal women undergoing weight management. The research indicates that those receiving menopausal hormone therapy experienced 35% greater weight loss while taking tirzepatide, a medication already approved by the Food and Drug Administration for the treatment of overweight and obesity.

The Connection Between Menopause, Weight, and Health

Menopause is associated with accelerated age-related weight gain and an increased risk of developing obesity. These conditions are significant risk factors for serious health issues, including cardiovascular disease and type 2 diabetes. The decline in estrogen levels during menopause can also contribute to cardiovascular risk independently of weight changes.

Study Findings and Expert Commentary

“This study provides important insights for developing more effective and personalized strategies for managing cardiometabolic risk in postmenopausal women,” stated Regina Castaneda, M.D., a postdoctoral research fellow at Mayo Clinic and the lead author of the study. The research team reviewed data from 120 participants with overweight or obesity who had been taking tirzepatide for weight management for at least 12 months.

Did You Know? Hormone therapy is currently considered the most effective first-line treatment for managing common menopausal symptoms like hot flashes and night sweats, affecting up to 75% of women.

Participants who were also receiving hormone therapy were compared to those with similar characteristics who were not. While the study showed a significant difference in weight loss, researchers emphasize that it was observational in nature. “In this observational study, women who used menopausal hormone therapy lost about 35% more weight than women taking tirzepatide alone. Because this was not a randomized trial, we cannot say hormone therapy caused additional weight loss,” explained Maria Daniela Hurtado Andrade, M.D., Ph.D., an endocrinologist at Mayo Clinic and senior author of the study.

Researchers acknowledge that women using hormone therapy may have already been more inclined towards healthy behaviors, or that symptom relief may have improved sleep and overall quality of life, contributing to better engagement with diet and exercise. Previous research has indicated that postmenopausal women using hormone therapy also experienced greater weight loss when treated with another GLP-1-based medication, semaglutide.

Expert Insight: The observed difference in weight loss is substantial enough to warrant further investigation into the interplay between hormone therapy and GLP-1-based medications. Preclinical data suggest a potential synergistic effect, where estrogen may enhance the appetite-suppressing properties of GLP-1.

Future Research Directions

The Mayo Clinic team plans to conduct a randomized clinical trial to further explore these findings. This future research will aim to determine if the benefits extend beyond weight loss, specifically examining whether hormone therapy can also enhance the effects of these medications on cardiometabolic health measures. “If confirmed, this work could speed the development and adoption of new, evidence-based strategies to reduce this risk for millions of postmenopausal women navigating this life stage,” added Dr. Hurtado Andrade.

Frequently Asked Questions

What was the primary focus of this study?

The study investigated whether menopausal hormone therapy influenced the effectiveness of tirzepatide for weight loss in postmenopausal women.

How many participants were involved in the study?

The study reviewed data from 120 participants with overweight or obesity who were receiving tirzepatide for weight management.

What is tirzepatide?

Tirzepatide is a Food and Drug Administration-approved medication used for the treatment of overweight and obesity.

As research continues to unravel the complex relationship between hormones, metabolism, and weight management, could these findings lead to more tailored and effective treatment approaches for postmenopausal women?